Down 32% With a 5.5% Yield, Is This High-Yield Dividend Stock Too Cheap to Ignore, and Worth Buying in December?

Campbell’s shares tumbled 5.2% after fiscal Q1 2026 results and guidance disappointed: net sales fell 3% and adjusted EPS declined 13%, and management now expects roughly flat organic sales with a 12–18% drop in adjusted EPS to $2.40–$2.55, leaving the stock down about 32% YTD and trading near its lowest level since 2008. Inflationary cost pressure and consumers resisting price increases have weighed on margins—particularly discretionary snack categories bought with Snyder’s‑Lance—while meals and beverages (e.g., V8, low‑sodium soups) are more resilient and management is pursuing premiumization, health‑and‑wellness positioning and cost reductions. The dividend remains intact at $1.56 annually (roughly a 5.5% yield and an implied ~63% payout at midpoint guidance), and the shares trade at about 11.5x FY26 midpoint EPS versus a 10‑year median P/E of 21.1, making Campbell’s a high‑yield, value‑oriented candidate for income investors who can tolerate near‑term, industry‑wide earnings pressure.

Analysis

Shares of Campbell Soup (CPB) fell 5.2% on the earnings release and are down ~32% year-to-date, trading near their lowest level since 2008 as investors reacted to disappointing fiscal Q1 2026 results and weak guidance; the sell-off has pushed the dividend yield to about 5.5% versus the S&P 500's 1.1%. Campbell's reported a 3% decline in net sales and a 13% drop in adjusted EPS in Q1, and reiterated full-year guidance calling for roughly flat organic sales and a 12%–18% decline in adjusted EPS to $2.40–$2.55.

The company points to industrywide consumer pullback and inflationary cost pressure that it has been unable to fully pass through, with discretionary snack categories (post-2018 Snyder's-Lance acquisition) underperforming while meals and beverage brands such as V8 show more resilience; management is pivoting toward premiumization, health-and-wellness positioning and cost reductions. Campbell's dividend remains $1.56 annually, implying a ~63% payout ratio at the midpoint of guidance, and the shares trade at ~11.5x the FY26 midpoint EPS versus a 10-year median P/E of 21.1, signaling valuation compression.

Given the guidance is unchanged from September, near-term upside is dependent on margin recovery and stabilization in consumer demand rather than positive surprises; the risks are industry-wide slower consumer spending and sustained inability to pass through inflation, while the primary upside is value capture if sales and margins improve.

Key Decisions for Investors

• Consider initiating a modest, size-limited position for income-oriented portfolios given the ~5.5% yield and ~11.5x FY26 midpoint EPS valuation, but cap exposure because management expects a 12%–18% EPS decline and the payout ratio is near 63%,
• Monitor the next two quarterly prints for sequential improvement in organic sales, gross-margin recovery and any EPS-upward revision before adding to positions; use confirmed margin pass-through or stronger-than-expected sales as a signal to scale in,
• Avoid allocating CPB to growth mandates and consider hedging or maintaining cash reserves given industrywide consumer pullback and discretionary snack weakness that could extend downside pressure.